未登录 分享 收藏
IK-595, a best-in-class MEK-RAF molecular glue, drives broad and potent anti-tumor activity across RAS-MAPK pathway-altered cancers as a monotherapy and in combination Haines, Eric; Catterall, Rachel; De Jesus, Victor; Hidalgo, Daniel; Cavanaugh, Jill; Sanchez-Martin, Marta; Manna, Joseph D.; Burke, Michael; Li, Bin; Wessel, Sarah R.; Yang, Ao; Santillana, Sergio; Ecsedy, Jeffrey; Zhang, X. Michelle; Ruppel, Sabine K. 分享 收藏
IK-595, a best-in-class MEK-RAF complex inhibitor, drives broad and potent anti-tumor activity in RAS/RAF-driven tumors Abstract Haines, Eric; Catterall, Rachel; De Jesus, Victor; Li, Bin; Wessel, Sarah R.; Cavanaugh, Jill; Burke, Michael; Manna, Joseph D.; Zavidij, Okzana; Yang, Ao; Xu, Lan; Santillana, Sergio; Ecsedy, Jeffrey; Zhang, X. Michelle; Ruppel, Sabine K. 分享 收藏
IK-595, a MEK-RAF complex inhibitor, obviates CRAF mediated resistance resulting in superior RAS/MAPK pathway inhibition and anti-tumor activity in RAS/RAF altered cancers Haines, Eric; Burke, Michael; Catterall, Rachel; De Jesus, Victor; Li, Bin; Manna, Joseph D.; Punkosdy, George; Zavidij, Oksana; Wessel, Sarah R.; Werosta, Grace; Cavanaugh, Jill; Newhouse, Sheila; Basavapathruni, Aravind; Xu, Lan; Santillana, Sergio; Zhang, Michelle; Ruppel, Sabine K. 分享 收藏
INITIAL RESULTS FROM A PHASE 1A/B STUDY OF IK175, AN ORAL AHR INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS AND UROTHELIAL CARCINOMA Aggen, David; McKean, Meredith; Lakhani, Nehal; Bashir, Babar; Hoffman-Censits, Jean; Alhalabi, Omar; Guancial, Elizabeth; Bowman, Isaac; Tan, Alan; Lingaraj, Trupti; Timothy, Marissa; Ortiz-Otero, Nerymar; Bartolini, Wilmin; Kacena, Katherine; Malek, Karim; Santillana, Sergio; Luke, Jason 分享 收藏
A PHASE 1B OPEN-LABEL, SINGLE-ARM DOSE EXPANSION STUDY OF IK-175, AN ORAL AHR INHIBITOR, IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH PRIMARY PD-1 INHIBITOR RESISTANT ADVANCED HEAD AND NECK CANCER Lingaraj, Trupti; Timothy, Marissa; Ortiz-Otero, Nerymar; Bartolini, Wilmin; Kacena, Katherine; Malek, Karim; Santillana, Sergio 分享 收藏
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) (vol 31, pg 79, 2020) Kundranda, M.; Gracian, A. C.; Zafar, S. F.; Meiri, E.; Bendell, J.; Algul, H.; Rivera, F.; Ahn, E. R.; Watkins, D.; Pelzer, U.; Charu, V.; Zalutskaya, A.; Kuesters, G.; Pipas, J. M.; Santillana, S.; Askoxylakis, V.; Ko, A. H. 分享 收藏
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) Kundranda, M.; Gracian, A. C.; Zafar, S. F.; Meiri, E.; Bendell, J.; Alguel, H.; Rivera, F.; Ahn, E. R.; Watkins, D.; Pelzer, U.; Charu, V; Zalutskaya, A.; Kuesters, G.; Pipas, J. M.; Santillana, S.; Askoxylakis, V; Ko, A. H. 分享 收藏
分享 收藏
Planning cancer control in Latin America and the Caribbean Goss, Paul E.; Lee, Brittany L.; Badovinac-Crnjevic, Tanja; Strasser-Weippl, Kathrin; Chavarri-Guerra, Yanin; St Louis, Jessica; Villarreal-Garza, Cynthia; Unger-Saldana, Karla; Ferreyra, Mayra; Debiasi, Marcio; Liedke, Pedro E. R.; Touya, Diego; Werutsky, Gustavo; Higgins, Michaela; Fan, Lei; Vasconcelos, Claudia; Cazap, Eduardo; Vallejos, Carlos; Mohar, Alejandro; Knaul, Felicia; Arreola, Hector; Batura, Rekha; Luciani, Silvana; Sullivan, Richard; Finkelstein, Dianne; Simon, Sergio; Barrios, Carlos; Kightlinger, Rebecca; Gelrud, Andres; Bychkovsky, Vladimir; Lopes, Gilberto; Stefani, Stephen; Blaya, Marcelo; Souza, Fabiano Hahn; Santos, Franklin Santana; Kaemmerer, Alberto; de Azambuja, Evandro; Cardona Zorilla, Andres Felipe; Murillo, Raul; Jeronimo, Jose; Tsu, Vivien; Carvalho, Andre; Gil, Carlos Ferreira; Sternberg, Cinthya; Duenas-Gonzalez, Alfonso; Sgroi, Dennis; Cuello, Mauricio; Fresco, Rodrigo; Reis, Rui Manuel; Masera, Guiseppe; Gabus, Raul; Ribeiro, Raul; Knust, Renata; Ismael, Gustavo; Rosenblatt, Eduardo; Roth, Berta; Villa, Luisa; Lara Solares, Argelia; Ximena Leon, Marta; Torres-Vigil, Isabel; Covarrubias-Gomez, Alfredo; Hernandez, Andres; Bertolino, Mariela; Schwartsmann, Gilberto; Santillana, Sergio; Esteva, Francisco; Fein, Luis; Mano, Max; Gomez, Henry; Hurlbert, Marc; Durstine, Alessandra; Azenha, Gustavo 分享 收藏
Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study). Abulkhair, O.; Uslu, R.; Sezgin, C.; Bueyuekberber, S.; Darwish, T.; Isikdogan, A.; Gumus, M.; Dane, F.; Sevinc, A.; Halawani, H.; Uncu, D.; Marrero, N.; Tobler, J.; Soares, C.; Landis, S.; Moraes, E.; Gidekel, R.; Santillana, S.; Nunez, P.; Cagnolati, S.; Rodriguez, J. G. 分享 收藏
分享 收藏
分享 收藏
分享 收藏
Neoadjuvant cisplatin (P) 5-fluoracilo (5-FU) and radiation therapy (RT) for organ preservation in squamous cell carcinoma of the head and neck: A single institutional experience Carracedo, C; Travezan, R; Postigo, J; Sanchez, P; Zaharia, M; Santillana, S; Casanova, L; Rodriguez, W; Gomez, H; Leon, J; Vallejos, C 分享 收藏
Relative dose intensity (RDI) related to international prognostic index (IPI) in chemosensitive elderly patients with aggressive non-hodgkin lymphoma (NHL). No benefits on disease-free survival (DFS) in high-risk patients Gomez, H; Medina, R; Casanova, L; Valdivia, S; Rodriguez, W; Carracedo, C; Santillana, S; Leon, J; Flores, C; Vallejos, C 分享 收藏
分享 收藏
.png){kind=icon}
未登录.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
